ライフサイエンスコーパス: amphotericin B

1 ving caspofungin and 539 receiving liposomal amphotericin B).

2 eceive voriconazole, and 10 were switched to amphotericin B.

3 anomolar antifungal activity in synergy with amphotericin B.

4 ique in its ability to develop resistance to amphotericin B.

5 i that is inherently resistant to azoles and amphotericin B.

6 d to the ion channel-forming natural product amphotericin B.

7 ients (53%) were also treated with liposomal amphotericin B.

8 f >28 and 2 times higher potency compared to amphotericin B.

9 the ion channel and antifungal activities of amphotericin B.

10 reased susceptibility to the antifungal drug amphotericin B.

11 id chromatography-MS-MS were used to measure amphotericin B.

12 ure the antifungal effect of macrophages and amphotericin B.

13 ients before and 3-4 wk after treatment with Amphotericin B.

14 ith an efficacy similar to that of liposomal amphotericin B.

15 e fungal burden when combined with liposomal amphotericin B.

16 of the antifungal effect of macrophages and amphotericin B.

17 ical debridement, in addition to intravenous amphotericin B.

18 zoles was delayed in comparison to that with amphotericin B.

19 gainst mucormycosis with efficacy similar to amphotericin B.

20 ve alternative that is better tolerated than amphotericin B.

21 erreus isolates frequently were resistant to amphotericin B.

22 d antifungals: fluconazole, caspofungin, and amphotericin B.

23 y against the strains tested was shown to be amphotericin B.

24 oxic effects at the maximal concentration of amphotericin B.

25 tant to the antifungal drugs fluconazole and amphotericin B.

26 zole was the most affected drugs followed by amphotericin B.

27 mug/ml), isavuconazole (4 and 4 mug/ml), and amphotericin B (0.25 and 0.5 mug/ml).

28 Participants received amphotericin B (0.7 to 1.0 mg per kilogram of body weigh

29 Control limits (amphotericin B, 1 to 4 microg/ml; itraconazole, 0.06 to

30 mycetes), BBL caspofungin 5-microg disk, and amphotericin B 10-microg (zygomycetes only).

31 voriconazole (10 mg/kg p.o. BID), liposomal amphotericin B (10 mg/kg intraperitoneally [i.p.] once a

32 were as follows: P. variotii ATCC MYA-3630, amphotericin B (15 to 24 mm), itraconazole (20 to 31 mm)

33 e (33 to 43 mm); A. fumigatus ATCC MYA-3626, amphotericin B (18 to 25 mm), itraconazole (11 to 21 mm)

34 d voriconazole (25 to 33 mm); and C. krusei, amphotericin B (18 to 27 mm), itraconazole (18 to 26 mm)

35 er applying topical natamycin (5 %), topical amphotericin B (1mg/ml), topical fluconazole (2mg/ml) an

36 minimum inhibitory concetrations (MICs) for amphotericin B (2.6 +/- 3.5 mug/mL), fluconazole (36.9 +

37 iaceus died despite treatment with liposomal amphotericin B, 3 mg/kg/d, and a young girl with pemphig

38 oodstream infection isolates of C. krusei to amphotericin B (304 isolates), flucytosine (254 isolates

39 patient was treated initially with liposomal amphotericin B, 430 mg daily, but changed to voriconazol

40 ungin (24%), voriconazole (8%), or liposomal amphotericin B (5%).

41 r caspofungin and 33.7 percent for liposomal amphotericin B (95.2 percent confidence interval for the

42 Isolates remained highly susceptible to amphotericin B (99% susceptibility at a MIC of < or = 1

43 as observed for all three antifungal agents: amphotericin B, 99.1% and 97%, respectively; flucytosine

44 (P), flucytosine (FC), caspofungin (C), and amphotericin B (A) were tested with 212 Candida isolates

45 Here, we describe that amphotericin B activates these cells through engaging My

46 ailable in Africa and most of Asia, and safe amphotericin B administration requires patient hospitali

47 upplemented with different concentrations of amphotericin B after inoculation with Candida albicans i

48 ainst T. cruzi and slightly more potent than amphotericin B against L. amazonensis.

49 We conclude that RIT is more effective than amphotericin B against systemic infection with C. neofor

50 B and flucytosine than among those receiving amphotericin B alone (15 vs. 25 deaths by day 14; hazard

51 tericin B plus flucytosine, as compared with amphotericin B alone, is associated with improved surviv

52 shown to reduce mortality, as compared with amphotericin B alone.

53 luation of two novel PEG amide conjugates of amphotericin B (AMB (1)): AB1 (4) and AM2 (5).

54 p<0.001), and more likely to be treated with amphotericin B (AmB) (87% vs 24%, p<0.001) and flucytosi

55 s genome equivalents in animals treated with amphotericin B (AMB) (95% confidence interval, 3.38 to 3

56 amestolkiae The potent in vitro activity of amphotericin B (AMB) and terbinafine (TRB) and of the ec

57 gillus Study (GCAS) compared voriconazole to amphotericin B (AmB) deoxycholate for the primary therap

58 of 10 patients with lung infection received amphotericin B (AMB) induction therapy (6 with 5-flucyto

59 Amphotericin B (AmB) is a clinically vital antimycotic b

60 Amphotericin B (AmB) is a prototypical small molecule na

61 Amphotericin B (AmB) is an effective but toxic antifunga

62 The membrane-active antifungal agent amphotericin B (AmB) is one of the few agents shown to s

63 Amphotericin B (AmB) is the archetype for small molecule

64 Amphotericin B (AmB) is the standard antifungal drug use

65 Amphotericin B (AMB) is used to treat both fungal and le

66 Current standard initial therapy consists of amphotericin B (AmB) plus flucytosine (5-FC), but 5-FC r

67 stance to the ergosterol-targeting fungicide amphotericin B (AmB) revealed that the two growth modes

68 ine A (CSA) to enhance the activity of PHMB, amphotericin B (AMB), and voriconazole (VCZ) against Asp

69 We determined species-specific ECVs for amphotericin B (AMB), flucytosine (FC) and itraconazole

70 Amphotericin B (AmB), is a highly effective antileishman

71 tute (CLSI) M38-A2 broth dilution method for amphotericin B (AMB), itraconazole (ITR), voriconazole (

72 e third major antifungal used in the clinic, amphotericin B (AmB), remains extremely rare despite 50

73 Amphotericin B (AmB), the most effective drug against le

74 Susceptibility against amphotericin B (AmB), voriconazole (VCZ), and natamycin

75 hat has the ability to develop resistance to amphotericin B (AmB).

76 h 30 mg/kg body weight intravenous liposomal amphotericin B (AmBisome) divided as 6 equal dose infusi

77 This polymer is slightly less effective than amphotericin B (AmpB) for two strains, but the polymer i

78 For amphotericin B, an MIC of </=0.5 mug/ml was significantl

79 ntrol organisms displayed 80% inhibition for amphotericin B and 50% inhibition for caspofungin as mea

80 e surgical and antifungal therapy (liposomal amphotericin B and a broad-spectrum triazole pending myc

81 rd, systemic injections of nontoxic doses of amphotericin B and another activator, macrophage colony-

82 probes for determination of MICs (FMICs) of amphotericin B and caspofungin against Candida spp. and

83 ism-based method of determination of MICs of amphotericin B and caspofungin against Candida spp. and

84 hin one well dilution, with the MICs against amphotericin B and caspofungin for all species.

85 agreement (79 to 100%) with the MICs of both amphotericin B and caspofungin for all species.

86 All isolates tested were susceptible to amphotericin B and caspofungin, but 11% were resistant o

87 For amphotericin B and caspofungin, the FMIC end point was t

88 and had reduced in vitro susceptibilities to amphotericin B and caspofungin, which correlated with cl

89 -mediated direct binding interaction between amphotericin B and ergosterol is required for both formi

90 omoting a direct binding interaction between amphotericin B and ergosterol.

91 isolates of Candida albicans were tested for amphotericin B and fluconazole susceptibilities by the N

92 In addition, amphotericin B and fluconazole were tested as control dr

93 ns and Cryptococcus neoformans comparable to amphotericin B and fluconazole.

94 ong with combination antifungal therapy with amphotericin B and fluconazole.

95 dely accepted treatment guidelines recommend amphotericin B and flucytosine as first-line induction t

96 d by days 14 and 70 among patients receiving amphotericin B and flucytosine than among those receivin

97 to 24, 48, and 72 h), and (iii) seven disks (amphotericin B and itraconazole 10-microg disks, voricon

98 India has spawned new treatment approaches--amphotericin B and its lipid formulations, injectable pa

99 trategy and the use of lipid formulations of amphotericin B and major surgery when feasible as the mo

100 potentiates the activity of the antifungals amphotericin B and micafungin.

101 He was treated with liposomal amphotericin B and multiple debridements, with no diseas

102 nazole that was similar to that reported for amphotericin B and posaconazole.

103 cormycosis to guide the timely initiation of amphotericin B and possible surgical intervention, a coo

104 tro and in vivo antagonism between liposomal amphotericin B and ravuconazole in simultaneous treatmen

105 for mortality, whereas lipid formulations of amphotericin B and surgery improved outcomes.

106 Whether the interaction between amphotericin B and triazoles is antagonistic against inv

107 EAs for amphotericin B and voriconazole were >90% for most poten

108 ic gramicidin and the known antifungal agent amphotericin B and were not toxic at their antifungal MI

109 ant strains of E.coli, as well as effects of amphotericin-B and miconazole on S. cerevisiae through t

110 nts (voriconazole, with or without liposomal amphotericin B), and 24 required surgical debridement.

111 olates were resistant to fluconazole, 35% to amphotericin B, and 7% to echinocandins; 41% were resist

112 e, voriconazole, itraconazole, posaconazole, amphotericin B, and caspofungin for 383 invasive Candida

113 he activity of the antifungals posaconazole, amphotericin B, and caspofungin, likely through increasi

114 l drugs, including amphotericin B, liposomal amphotericin B, and flucytosine, need to be much more wi

115 om all control rabbits, from 3 that received amphotericin B, and from 0 that received caspofungin.

116 in combination with antibiotics (vancomycin, amphotericin B, and nalidixic acid), and the efficacy of

117 manials (antimony, miltefosine, paromomycin, amphotericin B, and pentamidine).

118 porium infections are generally resistant to amphotericin B, and Scedosporium prolificans strains are

119 of fluconazole, voriconazole, posaconazole, amphotericin B, anidulafungin, caspofungin, and micafung

120 ty of caspofungin as compared with liposomal amphotericin B as empirical antifungal therapy.

121 erior efficacy compared with older azoles or amphotericin B as first-line or empiric therapy for fung

122 , voriconazole, was superior to conventional amphotericin B as primary therapy for invasive aspergill

123 0x minimum inhibitory concentration (MIC) or amphotericin B at 0.25x, 0.5x, 1x, or 10x MIC.

124 trols, with the exception of Optisol-GS plus amphotericin B at 10x MIC, donor corneas in supplemented

125 All patients received amphotericin B at a dose of 1 mg per kilogram of body we

126 rneas stored in Optisol-GS supplemented with amphotericin B at any concentration compared with paired

127 Two vials each were supplemented with amphotericin B at concentrations of 0.06, 0.12, or 0.225

128 Combinations of 12f with fluconazole and amphotericin B at subinhibitory concentration were syner

129 m 17 centres worldwide, who received primary amphotericin B-based treatment, and were analysed for da

130 rvival rates and potentiated the activity of amphotericin B. bFGF-containing regimens were associated

131 ically important antifungals nystatin A1 and amphotericin B, but it has several distinctive structura

132 The patient initially received liposomal amphotericin B, but the infection continued to progress,

133 traconazole, posaconazole, voriconazole, and amphotericin B by CLSI methods.

134 0.076) and Etest (1.00, SE = 0.218) and for amphotericin B by disk diffusion (1.00, SE = 0.098).

135 Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole,

136 usceptibility of 183 filamentous isolates to amphotericin B, caspofungin, itraconazole, posaconazole,

137 The MICs of the comparator drugs amphotericin B, caspofungin, micafungin, and voriconazol

138 ectrum-beta-lactamase (ESBL) and vancomycin, amphotericin B, ceftazidime, and clindamycin (VACC) plat

139 ssion, lipid biosynthesis, susceptibility to amphotericin B, cellular metabolism, and protein phospho

140 ortality rate, whereas lipid formulations of amphotericin B compared with amphotericin B deoxycholate

141 days in lung transplant recipients achieved amphotericin B concentrations in ELF above minimum inhib

142 Amphotericin B concentrations were measurable for all do

143 ition; 4 corneas each received the different amphotericin B concentrations.

144 Colorimetric MICs of caspofungin and amphotericin B corresponded to the first blue well (no g

145 is meta-analysis of 13 studies revealed that amphotericin B delivered as a locally prepared lipid emu

146 we defined the effect of the combination of amphotericin B deoxycholate (AmB) and 5-fluorocytosine (

147 Aerosolized administrations of amphotericin B deoxycholate (AmBd) and amphotericin B li

148 Since the late 1950s, intrathecal (IT) amphotericin B deoxycholate (AmBd) has been successfully

149 py or culture, to receive either intravenous amphotericin B deoxycholate (amphotericin) (219 patients

150 formulations of amphotericin B compared with amphotericin B deoxycholate (OR 0.09, 95% CI 0.02-0.50,

151 Combination antifungal therapy (amphotericin B deoxycholate and flucytosine) is the reco

152 R) of 3 cryptococcal induction regimens: (1) amphotericin B deoxycholate for 4 weeks; (2) amphoterici

153 lly allocated to a control arm or to receive amphotericin B deoxycholate or caspofungin treatment whi

154 wenty-four of 34 patients (71%) treated with amphotericin B deoxycholate, 4/12 (33%) treated with a t

155 Guidelines recommend initial treatment with amphotericin B deoxycholate, but this drug has substanti

156 s on three old, off-patent antifungal drugs: amphotericin B deoxycholate, flucytosine, and fluconazol

157 rming units from the lung and brain, whereas amphotericin B did not decrease the number of colony-for

158 zone diameters (-0.42) precludes the use of amphotericin B disk diffusion for susceptibility testing

159 Treatment with ergosterol-specific amphotericin B does not.

160 All patients received inhaled amphotericin B during their initial LT hospitalization,

161 that SensiQuattro performed best in testing amphotericin B (EA, 100%), voriconazole (EA, 93.7%), and

162 emented with a 0.255-mug/mL concentration of amphotericin B effectively eliminated fungal contaminant

163 th concentrations of 0.06 and 0.12 mug/mL of amphotericin B eliminated all fungal contaminants by day

164 ented with the 0.255-mug/mL concentration of amphotericin B eliminated all fungal contaminants by day

165 rgery and treatment with high-dose liposomal amphotericin B eradicated the disease.

166 Good reproducibility was demonstrated for amphotericin B, fluconazole, and voriconazole MICs deter

167 e diseases have been published and recommend amphotericin B, fluconazole, or caspofungin as the prima

168 C. krusei) against seven antifungal agents (amphotericin B, fluconazole, voriconazole, posaconazole,

169 Resistance to amphotericin B, flucytosine, and fluconazole was < or =

170 ns, and 426 isolates of Candida spp. against amphotericin B, flucytosine, and voriconazole.

171 We examined the susceptibilities to amphotericin B, flucytosine, fluconazole, posaconazole,

172 The MICs of amphotericin B, flucytosine, fluconazole, voriconazole,

173 ailable for older antifungal agents, such as amphotericin B, flucytosine, or itraconazole.

174 st MICs (94 to 97%) and by both methods with amphotericin B for all species (95 to 99.3%).

175 nospecies biofilms reduced susceptibility to amphotericin B for C. tropicalis and C. glabrata.

176 rical therapy with conventional or liposomal amphotericin B for the prevention and early treatment of

177 mbar puncture if antigen-positive and either amphotericin-B for those with CNS disease or fluconazole

178 ring an echinocandin with either an azole or amphotericin B formulation as therapy for invasive asper

179 .4%) patients were initially treated with an amphotericin B formulation for a median duration of 2 we

180 infections in patients receiving aerosolized amphotericin B formulations as sole prophylaxis was dete

181 The enhanced understanding of amphotericin B function derived from these synthesis-ena

182 gin, amphotericin B, or lipid formulation of amphotericin B given as either empirical or culture-base

183 s often in the caspofungin group than in the amphotericin B group (10.3 percent vs. 14.5 percent, P=0

184 sine or high-dose fluconazole with high-dose amphotericin B improved survival at 14 and 70 days.

185 We have evaluated liposomal amphotericin B in 20 patients with DL in an open clinica

186 % and antifungals in 87% of cases (liposomal amphotericin B in 61%).

187 mucormycosis and compared its efficacy with amphotericin B in a matched case-control analysis.

188 Concentrations of amphotericin B in ELF (median, 25-75 IQR) were at 4 hr (

189 ffusion methods for testing posaconazole and amphotericin B in the clinical laboratory against the sp

190 ospectively determined the concentrations of amphotericin B in the epithelial lining fluid (ELF) and

191 Administration of polymyxin/tobramycin/amphotericin B in the oropharynx and the gastric tube pl

192 We show here that amphotericin B induces signal transduction and inflammat

193 eved with intravenous phospholipid-complexed amphotericin B initially, followed by long-term combinat

194 ceptibility to oral fluconazole, intravenous amphotericin B, intravitreal amphotericin B, oral vorico

195 cans cells were resistant to fluconazole and amphotericin B, irrespective of the medium used to form

196 mphogel, a dextran-based hydrogel into which amphotericin B is adsorbed.

197 usly reported that the antifungal medication amphotericin B is an activator of circulating monocytes,

198 Liposomal amphotericin B is an effective therapy for DL, with a hi

199 Amphotericin B is the archetype for small molecules that

200 sceptibility data for Chrysosporium zonatum, amphotericin B is the most active drug, itraconazole sus

201 vious severe infusion reactions to liposomal amphotericin B is unclear.

202 The drugs tested were amphotericin B, itraconazole, posaconazole, voriconazole

203 t our isolates appeared to be susceptible to amphotericin B, itraconazole, voriconazole, ravuconazole

204 orting comparisons of fluconazole, liposomal amphotericin B (L-AmB), itraconazole, micafungin and pla

205 The optimal dosage of liposomal amphotericin B (LAmB) alone or in combination with flucy

206 ity of high-dose weekly (10 mg/kg) liposomal amphotericin B (LamB) for antifungal prophylaxis in live

207 ed-dendrimer (PDD), complexed with liposomal amphotericin B (LAmB) in an L. major mouse model and ana

208 ns of amphotericin B deoxycholate (AmBd) and amphotericin B lipid complex (ABLC) in lung transplant r

209 y of targeted prophylaxis with micafungin or amphotericin B lipid complex (ABLC) was assessed in a se

210 We evaluated once weekly intravenous amphotericin B lipid complex (ABLC), given its broad-spe

211 a tertiary care cancer center and found that amphotericin B lipid complex administration was uneventf

212 r aerosolized nebulization (AeroEclipse), of amphotericin B lipid complex at 1 mg/kg every 24 hr for

213 stration through aerosolized nebulization of amphotericin B lipid complex every 24 hr for 4 days in l

214 conazole after therapy with itraconazole and amphotericin B lipid complex failed.

215 ist regarding the pharmacokinetic profile of amphotericin B lipid complex in lung transplant recipien

216 The tolerability of amphotericin B lipid complex in patients with previous s

217 Additionally, antifungal drugs, including amphotericin B, liposomal amphotericin B, and flucytosin

218 esistance to amphotericin B, we conducted an amphotericin B loss-of-function screen in Chinese hamste

219 sistance to the cholesterol-binding compound amphotericin B methyl ester (AME) by acquiring mutations

220 sm by which the cholesterol-binding compound amphotericin B methyl ester (AME) inhibits human immunod

221 eported that a cholesterol-binding compound, amphotericin B methyl ester (AME), blocks HIV-1 entry an

222 compound, the polyene antifungal antibiotic amphotericin B methyl ester (AME).

223 Decreased susceptibilities to amphotericin B (MIC at which 90% of isolates were inhibi

224 Amphotericin B (MIC(50),1 microg/ml) and flucytosine (MI

225 o identify two of the six isolates with high amphotericin B MICs.

226 nd carboxylic acid appendages on neighboring amphotericin B molecules are not required for ion channe

227 er the antimicrobial mixture of polymyxin B, amphotericin B, nalidixic acid, trimethoprim, and azloci

228 All isolates had MICs at 48 h of amphotericin B of > or = 1 microg/ml and of echinocandin

229 rlo simulations showed that human dosages of amphotericin B of at least 0.6 mg/kg were required to ac

230 Aspergillus terreus were studied with either amphotericin B or caspofungin.

231 ecific circumstances, including testing with amphotericin B or triazoles for non-Aspergillus molds (M

232 tration of an azole (OR, 0.06; P < 0.001) or amphotericin B (OR, 0.35; P = 0.05) was protective.

233 nventional therapy consisting of a triazole, amphotericin B, or a combination of both.

234 after infection with (213)Bi-18B7 antibody, amphotericin B, or both.

235 exposure of Rhizopus oryzae to itraconazole, amphotericin B, or caspofungin and exposure of Aspergill

236 ecific standard care (fluconazole, liposomal amphotericin B, or caspofungin) posttransplant.

237 Fluconazole, caspofungin, amphotericin B, or lipid formulation of amphotericin B g

238 le, intravenous amphotericin B, intravitreal amphotericin B, oral voriconazole, and intravitreal vori

239 tration showing absence of visual growth) of amphotericin B, overall agreement levels were 90 to 93%

240 Treatment with amphotericin B, particularly in combination with MCSF, i

241 Using simultaneous fura-2 Ca(2+) imaging and amphotericin B perforated patch-clamp electrophysiology,

242 Voltage-clamp experiments using amphotericin B-permeablized monolayers revealed that the

243 A survival benefit of amphotericin B plus fluconazole was not found.

244 The US guidelines recommend treatment with amphotericin B plus flucytosine for at least 2 weeks, fo

245 Amphotericin B plus flucytosine was associated with sign

246 Combination antifungal therapy (amphotericin B plus flucytosine) administered before or

247 Amphotericin B plus flucytosine, as compared with amphot

248 nts, the use of topical polymyxin/tobramycin/amphotericin B plus mupirocin/chlorhexidine was associat

249 Testing of susceptibility to amphotericin B, posaconazole, and voriconazole was subse

250 presented three important hydrogen bonds and amphotericin B presented two hydrogen bonds that stabili

251 r perspectives for the use of 2 antifungals, amphotericin B products and posaconazole, with activity

252 The exception was amphotericin B (R values of 0.68 and 0.5 for disk and ta

253 Inhaled formulations of amphotericin B remain the most widely studied option for

254 antibiotic medium 3 (AM3) test to determine amphotericin B resistance in 5 of 30 Candida isolates.

255 ong antifungal activity against wildtype and amphotericin B-resistant strains of Candida albicans at

256 avuconazole, voriconazole, itraconazole, and amphotericin B, respectively.

257 These results do not prove that amphotericin B should be added to Optisol-GS; larger-sca

258 pofungin, micafungin, and terbinafine, while amphotericin B showed the least activity.

259 Comparison with clinically used amphotericin B shows similar antifungal behaviour withou

260 l inhibitory concentration of 2 mg/L against amphotericin B, suggesting resistance to the drug.

261 dy, 12 pairs of corneas were divided between amphotericin B supplementation and the control condition

262 light-exposed compared with light-protected amphotericin B-supplemented Optisol-GS was identified.

263 t, there was no growth of either organism in amphotericin B-supplemented vials, except at 0.25x and 0

264 ppears to be a useful method for determining amphotericin B susceptibilities of Candida species.

265 agreement of fluconazole, voriconazole, and amphotericin B susceptibility results by disk diffusion.

266 methylene blue (0.5 microg/ml) (MH-GMB) for amphotericin B susceptibility testing of 4,936 isolates

267 d isolates except zygomycetes, and 10-microg amphotericin B tablets against zygomycete isolates only.

268 e more likely to receive regimens containing amphotericin B than fluconazole as primary therapy.

269 For amphotericin B, the best correlation between reference M

270 i.Despite relapsing 6 weeks after completing amphotericin B therapy, the patient made a complete reco

271 ctively screened twice a week, and liposomal amphotericin-B therapy initiated based on a positive qPC

272 Each drug poses unique access challenges: amphotericin B through cost, toxic effects, and insuffic

273 solution using the Cl--permeable antibiotic amphotericin B to allow Cl- equilibration with the cell

274 y fungal infection, however, the addition of amphotericin B to Optisol-GS deserves further investigat

275 The addition of amphotericin B to Optisol-GS may significantly improve a

276 conazole cases was similar to 13 (39%) of 33 amphotericin B-treated matched controls (weighted all-ca

277 ART-naive adults aged>/=21 years initiating amphotericin B treatment for CM were randomized to ART i

278 therapy was additive with that of liposomal amphotericin B treatment.

279 active at the time of the IFI, and any prior amphotericin B use; among SOT recipients, fluconazole no

280 ntifungal agents, including lipid-associated amphotericin B, voriconazole, and caspofungin.

281 The species has a higher amphotericin B, voriconazole, and itraconazole MIC and c

282 data; antifungal susceptibility testing with amphotericin B, voriconazole, and itraconazole; and mole

283 r minimal effective concentrations (MECs) of amphotericin B, voriconazole, posaconazole, caspofungin,

284 The success rate with liposomal amphotericin B was 4-fold higher even when controlling f

285 Treatment with bFGF plus amphotericin B was associated with neutrophil influx int

286 Although liposomal amphotericin B was considered well tolerated, mild adver

287 The MIC for amphotericin B was defined as the lowest concentration o

288 formed mixed- Candida species biofilms while amphotericin B was potent.

289 Amphotericin B was selected as a membrane-active antifun

290 Liposomal amphotericin B was started within a median of 1 (interqu

291 cterize prevention of posttreatment relapse, amphotericin B was used to kill approximately 90-95% of

292 an be isolated on the basis of resistance to amphotericin B, we conducted an amphotericin B loss-of-f

293 To compare the efficacy of RIT with that of amphotericin B, we infected AJ/Cr mice intravenously wit

294 As determined by E-test, the MICs of amphotericin B were > or = 0.38 microg/ml for 10% of Can

295 nd generally better tolerated than liposomal amphotericin B when given as empirical antifungal therap

296 Members of this class include amphotericin B, which has been used widely to treat syst

297 al antifungal therapy, including intrathecal amphotericin B, while results of fungal cultures were pe

298 s inhibition could be overcome by the use of amphotericin B with a high [Cl-] pipette solution.

299 , and the adapter protein MyD88 responded to amphotericin B with NF-kappaB-dependent reporter activit

300 eeks, plus standard therapy with intravenous amphotericin B, with or without flucytosine, followed by